J. R. Mascola

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

This paper develops a prefusion-stabilized Lassa virus GPC, identifies a neutralizing nanobody, and reveals a cleavage-dependent site of vulnerability at the trimer apex.

The paper identifies six monoclonal antibodies that broadly neutralize coronaviruses by targeting the conserved fusion peptide.

This study applies Bcl-6/Bcl-xL retroviral transduction to isolate antibodies and generate B cell clones from various B cell populations in healthy and infected individuals.

This study shows that co-immunization with stem immunogens from group 1 and 2 influenza A HAs elicits cross-group neutralizing antibodies and protective immunity in multiple animal models.

This paper identifies an antibody, WS6, from a mouse immunized with SARS-CoV-2 spike mRNA, which neutralizes diverse beta-coronaviruses by targeting a conserved helical epitope on the S2 subunit.

The paper designs and produces molecular probes for SARS-CoV-2 variants to assess immune responses and isolate neutralizing antibodies.

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

This study identifies a lineage of antibodies from infected rhesus macaques that neutralize 54% of HIV-1 strains by expanding the antibody-Env interface around the V2 loop.

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

A broadly neutralizing antibody protects against multiple SARS-CoV and SARS-CoV-2 variants in mice by targeting a conserved epitope in the receptor-binding domain.

The paper analyzes monoclonal antibodies from vaccinated non-human primates to identify a conserved immunodominant epitope in HIV-1 Env and how different lineages target it for potent neutralization.

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

The paper isolates and characterizes cross-neutralizing antibodies from COVID-19 patients, identifying antibodies that neutralize both SARS-CoV-1 and SARS-CoV-2, including variants.

This study evaluates the neutralization resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to monoclonal antibodies and sera, finding increased resistance in B.1.351.

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

This study develops VLP-based vaccines targeting the HIV-1 FP8 epitope, showing they induce high-titer FP8-specific antibodies and effective neutralizing responses in mice.

This paper uses cryo-EM to show how SARS-CoV-2 spike protein undergoes pH-dependent structural changes that affect ACE2 binding and antibody evasion.

The paper develops biotin-labeled SARS-CoV-2 spike molecular probes using structure-based design and purification methods, achieving high yields and enabling antibody characterization.

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.

Nanoparticle immunogens with four seasonal influenza hemagglutinins elicit neutralizing antibodies against both the head and stem, providing broad protection against diverse influenza strains.

The paper develops a fluorescent reporter virus panel to enable high-throughput neutralization profiling of influenza antibodies without requiring high-containment labs.

This study shows that CD8β+ T cell depletion in SIV-infected macaques does not prevent viral control or protection from challenge, suggesting CD8β+ T cells are not essential for these outcomes.

This study designs nanoparticle-based influenza HA stem antigens that activate unmutated B cell receptors of broadly neutralizing antibodies, potentially enabling cross-group immunity.

The paper maps functional epitopes of antibodies targeting HIV Env fusion peptide by analyzing mutations affecting neutralization, revealing differences between vaccine- and infection-elicited antibodies.